Logo image of SCLX

SCILEX HOLDING CO (SCLX) Stock Fundamental Analysis

NASDAQ:SCLX - Nasdaq - US80880W2052 - Common Stock - Currency: USD

4.755  +0.01 (+0.32%)

Fundamental Rating

1

SCLX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of SCLX have multiple concerns. SCLX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SCLX has reported negative net income.
SCLX had a negative operating cash flow in the past year.
SCLX had negative earnings in 4 of the past 5 years.
In the past 5 years SCLX always reported negative operating cash flow.
SCLX Yearly Net Income VS EBIT VS OCF VS FCFSCLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

The Return On Assets of SCLX (-164.82%) is worse than 84.85% of its industry peers.
Industry RankSector Rank
ROA -164.82%
ROE N/A
ROIC N/A
ROA(3y)-63.75%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SCLX Yearly ROA, ROE, ROICSCLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 100 -100 200

1.3 Margins

SCLX has a better Gross Margin (66.45%) than 73.23% of its industry peers.
The Profit Margin and Operating Margin are not available for SCLX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.45%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SCLX Yearly Profit, Operating, Gross MarginsSCLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

0

2. Health

2.1 Basic Checks

SCLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
SCLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SCLX Yearly Shares OutstandingSCLX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 1M 2M 3M 4M
SCLX Yearly Total Debt VS Total AssetsSCLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -12.09, we must say that SCLX is in the distress zone and has some risk of bankruptcy.
SCLX has a Altman-Z score of -12.09. This is in the lower half of the industry: SCLX underperforms 75.25% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -12.09
ROIC/WACCN/A
WACC8.13%
SCLX Yearly LT Debt VS Equity VS FCFSCLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 100M -100M

2.3 Liquidity

SCLX has a Current Ratio of 0.19. This is a bad value and indicates that SCLX is not financially healthy enough and could expect problems in meeting its short term obligations.
SCLX has a Current ratio of 0.19. This is amonst the worse of the industry: SCLX underperforms 94.44% of its industry peers.
A Quick Ratio of 0.17 indicates that SCLX may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.17, SCLX is doing worse than 94.44% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.19
Quick Ratio 0.17
SCLX Yearly Current Assets VS Current LiabilitesSCLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.68%

3.2 Future

Based on estimates for the next years, SCLX will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.68% on average per year.
The Revenue is expected to grow by 110.43% on average over the next years. This is a very strong growth
EPS Next Y60.88%
EPS Next 2Y30.81%
EPS Next 3Y63.98%
EPS Next 5Y17.68%
Revenue Next Year109.9%
Revenue Next 2Y90.74%
Revenue Next 3Y95.48%
Revenue Next 5Y110.43%

3.3 Evolution

SCLX Yearly Revenue VS EstimatesSCLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
SCLX Yearly EPS VS EstimatesSCLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 20 -20 40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SCLX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SCLX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCLX Price Earnings VS Forward Price EarningsSCLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCLX Per share dataSCLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

SCLX's earnings are expected to grow with 63.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.81%
EPS Next 3Y63.98%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SCLX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCILEX HOLDING CO

NASDAQ:SCLX (5/22/2025, 9:57:52 AM)

4.755

+0.01 (+0.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-31 2025-03-31/amc
Earnings (Next)N/A N/A
Inst Owners20.39%
Inst Owner Change-8.48%
Ins Owners0.38%
Ins Owner Change-1.32%
Market Cap33.05M
Analysts80
Price Target324.27 (6719.56%)
Short Float %N/A
Short Ratio0.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-132.24%
Min EPS beat(2)-256.34%
Max EPS beat(2)-8.13%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.81%
Min Revenue beat(2)-19.06%
Max Revenue beat(2)15.44%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2885.13%
PT rev (3m)2885.13%
EPS NQ rev (1m)-3400%
EPS NQ rev (3m)-3400%
EPS NY rev (1m)0%
EPS NY rev (3m)-3400%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.71
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-20.3
EYN/A
EPS(NY)-7.94
Fwd EYN/A
FCF(TTM)-3.03
FCFYN/A
OCF(TTM)-2.98
OCFYN/A
SpS6.73
BVpS-24.88
TBVpS-32.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -164.82%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.45%
FCFM N/A
ROA(3y)-63.75%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.96%
Cap/Sales 0.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.19
Quick Ratio 0.17
Altman-Z -12.09
F-Score2
WACC8.13%
ROIC/WACCN/A
Cap/Depr(3y)20.05%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y60.88%
EPS Next 2Y30.81%
EPS Next 3Y63.98%
EPS Next 5Y17.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.68%
Revenue Next Year109.9%
Revenue Next 2Y90.74%
Revenue Next 3Y95.48%
Revenue Next 5Y110.43%
EBIT growth 1Y-375.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y9.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.59%
OCF growth 3YN/A
OCF growth 5YN/A